{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:12:57Z","timestamp":1789992777540,"version":"4.0.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s102573","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T23:18:10Z","timestamp":1463613490000},"page":"2945","source":"Crossref","is-referenced-by-count":26,"title":["Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential"],"prefix":"10.2147","author":[{"given":"Jacqueline C.","family":"Barrientos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,5]]},"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=30430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:46:57Z","timestamp":1477867617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/idelalisib-for-the-treatment-of-indolent-non-hodgkin-lymphoma-a-review-peer-reviewed-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ott.s102573","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}